| Experimental Factor Ontology (EFO) Information | |
| Identifier | EFO_0006335 |
| Description | The blood pressure during the contraction of the left ventricle of the heart. | Trait category |
Other measurement
|
| Synonyms |
2 synonyms
|
| Mapped terms |
3 mapped terms
|
| Polygenic Score ID & Name | PGS Publication ID (PGP) | Reported Trait | Mapped Trait(s) (Ontology) | Number of Variants | Ancestry distribution | Scoring File (FTP Link) |
|---|---|---|---|---|---|---|
| PGS000301 (GRS970_SBP) |
PGP000092 | Xie T et al. Circ Genom Precis Med (2020) |
Systolic blood pressure | systolic blood pressure | 970 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000301/ScoringFiles/PGS000301.txt.gz |
| PGS000900 (PRS_SBP_f) |
PGP000233 | Kauko A et al. Hypertension (2021) |
Systolic blood pressure (female) | systolic blood pressure, female |
1,098,015 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000900/ScoringFiles/PGS000900.txt.gz |
| PGS000901 (PRS_SBP_m) |
PGP000233 | Kauko A et al. Hypertension (2021) |
Systolic blood pressure (male) | systolic blood pressure, male |
1,098,015 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000901/ScoringFiles/PGS000901.txt.gz |
| PGS000913 (ukb_sbp_prs) |
PGP000240 | Vaura F et al. Hypertension (2021) |
Systolic blood pressure | systolic blood pressure | 1,098,015 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000913/ScoringFiles/PGS000913.txt.gz |
| PGS001134 (GBE_INI4080) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Systolic BP (AR) | systolic blood pressure | 15,481 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001134/ScoringFiles/PGS001134.txt.gz |
| PGS002009 (portability-PLR_systolic_BP) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Systolic blood pressure, automated reading | systolic blood pressure | 68,449 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002009/ScoringFiles/PGS002009.txt.gz |
| PGS002228 (portability-ldpred2_systolic_BP) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Systolic blood pressure, automated reading | systolic blood pressure | 937,030 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002228/ScoringFiles/PGS002228.txt.gz |
| PGS002257 (GRS901_SBP) |
PGP000283 | Evangelou E et al. Nat Genet (2018) |
Systolic blood pressure | systolic blood pressure | 884 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002257/ScoringFiles/PGS002257.txt.gz |
| PGS002275 (SBP-PRS) |
PGP000303 | Groenland EH et al. Atherosclerosis (2022) |
Systolic blood pressure | systolic blood pressure | 425 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002275/ScoringFiles/PGS002275.txt.gz |
|
PGS Performance Metric ID (PPM) |
Evaluated Score |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
|---|---|---|---|---|---|---|---|---|---|
| PPM000801 | PGS000301 (GRS970_SBP) |
PSS000371| European Ancestry| 288 individuals |
PGP000092 | Xie T et al. Circ Genom Precis Med (2020) |
Reported Trait: Systolic blood pressure (mmHg) | — | — | R²: 0.012 | Sex, age, age^2, BMI | — |
| PPM000771 | PGS000301 (GRS970_SBP) |
PSS000376| European Ancestry| 1,354 individuals |
PGP000092 | Xie T et al. Circ Genom Precis Med (2020) |
Reported Trait: Systolic blood pressure (mmHg) | — | — | R²: 0.0215 | Sex, age, age^2, BMI | — |
| PPM002648 | PGS000900 (PRS_SBP_f) |
PSS001169| European Ancestry| 123,579 individuals |
PGP000233 | Kauko A et al. Hypertension (2021) |
Reported Trait: Hypertension | HR: 1.42 [1.4, 1.44] | — | Hazard Ratio (HR, top 2.5% vs middle 60%): 2.12 [1.99, 2.25] | Age as timescale, collection year, genotyping batch, PCs(1-10) | — |
| PPM002650 | PGS000900 (PRS_SBP_f) |
PSS001169| European Ancestry| 123,579 individuals |
PGP000233 | Kauko A et al. Hypertension (2021) |
Reported Trait: Early-onset hypertension (< 55 years) | HR: 1.56 [1.53, 1.58] | — | Hazard Ratio (HR, top 2.5% vs middle 60%): 2.51 [2.32, 2.72] | Age as timescale, collection year, genotyping batch, PCs(1-10) | — |
| PPM002652 | PGS000900 (PRS_SBP_f) |
PSS001169| European Ancestry| 123,579 individuals |
PGP000233 | Kauko A et al. Hypertension (2021) |
Reported Trait: Late-onset hypertension (> 55 years) | HR: 1.31 [1.28, 1.33] | — | Hazard Ratio (HR, top 2.5% vs middle 60%): 1.66 [1.5, 1.84] | Age as timescale, collection year, genotyping batch, PCs(1-10) | — |
| PPM002649 | PGS000901 (PRS_SBP_m) |
PSS001170| European Ancestry| 95,213 individuals |
PGP000233 | Kauko A et al. Hypertension (2021) |
Reported Trait: Hypertension | HR: 1.27 [1.26, 1.29] | — | Hazard Ratio (HR, top 2.5% vs middle 60%): 1.8 [1.69, 1.92] | Age as timescale, collection year, genotyping batch, PCs(1-10) | — |
| PPM002651 | PGS000901 (PRS_SBP_m) |
PSS001170| European Ancestry| 95,213 individuals |
PGP000233 | Kauko A et al. Hypertension (2021) |
Reported Trait: Early-onset hypertension (< 55 years) | HR: 1.35 [1.32, 1.37] | — | Hazard Ratio (HR, top 2.5% vs middle 60%): 2.1 [1.94, 2.28] | Age as timescale, collection year, genotyping batch, PCs(1-10) | — |
| PPM002653 | PGS000901 (PRS_SBP_m) |
PSS001170| European Ancestry| 95,213 individuals |
PGP000233 | Kauko A et al. Hypertension (2021) |
Reported Trait: Late-onset hypertension (> 55 years) | HR: 1.21 [1.19, 1.23] | — | Hazard Ratio (HR, top 2.5% vs middle 60%): 1.45 [1.3, 1.61] | Age as timescale, collection year, genotyping batch, PCs(1-10) | — |
| PPM002970 | PGS000913 (ukb_sbp_prs) |
PSS001446| European Ancestry| 218,754 individuals |
PGP000240 | Vaura F et al. Hypertension (2021) |
Reported Trait: Early onset incident hypertension (< 55 years) | HR: 1.54 [1.53, 1.56] | — | Hazard Ratio (HR, top 2.5% vs middle 60%): 2.62 [2.48, 2.77] | Sex, collection year, genotyping batch, PCs(1-10) | — |
| PPM002971 | PGS000913 (ukb_sbp_prs) |
PSS001446| European Ancestry| 218,754 individuals |
PGP000240 | Vaura F et al. Hypertension (2021) |
Reported Trait: Late onset incident hypertension (≥55 years) | HR: 1.31 [1.29, 1.32] | — | Hazard Ratio (HR, top 2.5% vs middle 60%): 1.68 [1.57, 1.81] | Sex, collection year, genotyping batch, PCs(1-10) | — |
| PPM002977 | PGS000913 (ukb_sbp_prs) |
PSS001448| European Ancestry| 218,792 individuals |
PGP000240 | Vaura F et al. Hypertension (2021) |
Reported Trait: Incident cardiovascular disease | — | — | Hazard Ratio (HR, top 2.5% vs middle 60%): 1.3 [1.22, 1.39] | Sex, collection year, genotyping batch, PCs(1-10) | — |
| PPM002978 | PGS000913 (ukb_sbp_prs) |
PSS001447| European Ancestry| 218,792 individuals |
PGP000240 | Vaura F et al. Hypertension (2021) |
Reported Trait: Incident coronary heart disease | HR: 1.15 [1.13, 1.17] | — | Hazard Ratio (HR, top 2.5% vs middle 60%): 1.33 [1.23, 1.44] | Sex, collection year, genotyping batch, PCs(1-10) | — |
| PPM002979 | PGS000913 (ukb_sbp_prs) |
PSS001449| European Ancestry| 212,884 individuals |
PGP000240 | Vaura F et al. Hypertension (2021) |
Reported Trait: Incident stroke | — | — | Hazard Ratio (HR, top 2.5% vs middle 60%): 1.29 [1.16, 1.44] | Sex, collection year, genotyping batch, PCs(1-10) | — |
| PPM002981 | PGS000913 (ukb_sbp_prs) |
PSS001447| European Ancestry| 218,792 individuals |
PGP000240 | Vaura F et al. Hypertension (2021) |
Reported Trait: Incident coronary heart disease | — | C-index: 0.743 | — | Clinical atherosclerotic cardiovascular disease risk score (age, sex, total cholesterol, high density lipoprotein, antihypertensive medication, diabetes, current smoking) | — |
| PPM002982 | PGS000913 (ukb_sbp_prs) |
PSS001449| European Ancestry| 212,884 individuals |
PGP000240 | Vaura F et al. Hypertension (2021) |
Reported Trait: Incident stroke | — | C-index: 0.732 | — | Clinical atherosclerotic cardiovascular disease risk score (age, sex, total cholesterol, high density lipoprotein, antihypertensive medication, diabetes, current smoking) | — |
| PPM002969 | PGS000913 (ukb_sbp_prs) |
PSS001446| European Ancestry| 218,754 individuals |
PGP000240 | Vaura F et al. Hypertension (2021) |
Reported Trait: Incident hypertension | HR: 1.42 [1.41, 1.43] | — | Hazard Ratio (HR, top 2.5% vs middle 60%): 2.19 [2.1, 2.29] | Sex, collection year, genotyping batch, PCs(1-10) | — |
| PPM002975 | PGS000913 (ukb_sbp_prs) |
PSS001450| European Ancestry| 9,906 individuals |
PGP000240 | Vaura F et al. Hypertension (2021) |
Reported Trait: Incident hypertension | — | C-index: 0.802 | — | Age, sex, systolic blood pressure, diastolic blood pressure, body mass index, diabetes, current smoking | — |
| PPM002980 | PGS000913 (ukb_sbp_prs) |
PSS001448| European Ancestry| 218,792 individuals |
PGP000240 | Vaura F et al. Hypertension (2021) |
Reported Trait: Incident cardiovascular disease | — | C-index: 0.731 | — | Clinical atherosclerotic cardiovascular disease risk score (age, sex, total cholesterol, high density lipoprotein, antihypertensive medication, diabetes, current smoking) | — |
| PPM008400 | PGS001134 (GBE_INI4080) |
PSS007268| European Ancestry| 23,726 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Systolic BP (AR) | — | — | R²: 0.19444 [0.18561, 0.20326] Incremental R2 (full-covars): 0.04167 PGS R2 (no covariates): 0.04458 [0.03957, 0.04959] |
age, sex, UKB array type, Genotype PCs | — |
| PPM008398 | PGS001134 (GBE_INI4080) |
PSS007266| African Ancestry| 6,409 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Systolic BP (AR) | — | — | R²: 0.1028 [0.08882, 0.11678] Incremental R2 (full-covars): 0.00145 PGS R2 (no covariates): 0.00628 [0.00245, 0.01011] |
age, sex, UKB array type, Genotype PCs | — |
| PPM008399 | PGS001134 (GBE_INI4080) |
PSS007267| East Asian Ancestry| 1,634 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Systolic BP (AR) | — | — | R²: 0.22915 [0.19418, 0.26412] Incremental R2 (full-covars): 0.03474 PGS R2 (no covariates): 0.04463 [0.0255, 0.06375] |
age, sex, UKB array type, Genotype PCs | — |
| PPM008401 | PGS001134 (GBE_INI4080) |
PSS007269| South Asian Ancestry| 7,640 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Systolic BP (AR) | — | — | R²: 0.15314 [0.13847, 0.16782] Incremental R2 (full-covars): 0.02459 PGS R2 (no covariates): 0.0236 [0.01696, 0.03024] |
age, sex, UKB array type, Genotype PCs | — |
| PPM008402 | PGS001134 (GBE_INI4080) |
PSS007270| European Ancestry| 63,823 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Systolic BP (AR) | — | — | R²: 0.17232 [0.16713, 0.17751] Incremental R2 (full-covars): 0.04845 PGS R2 (no covariates): 0.04834 [0.04519, 0.0515] |
age, sex, UKB array type, Genotype PCs | — |
| PPM010946 | PGS002009 (portability-PLR_systolic_BP) |
PSS009494| European Ancestry| 18,717 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Systolic blood pressure, automated reading | — | — | Partial Correlation (partial-r): 0.2548 [0.2414, 0.2682] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010947 | PGS002009 (portability-PLR_systolic_BP) |
PSS009268| European Ancestry| 3,930 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Systolic blood pressure, automated reading | — | — | Partial Correlation (partial-r): 0.2702 [0.2409, 0.299] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010948 | PGS002009 (portability-PLR_systolic_BP) |
PSS008822| European Ancestry| 6,337 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Systolic blood pressure, automated reading | — | — | Partial Correlation (partial-r): 0.2197 [0.1961, 0.243] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010949 | PGS002009 (portability-PLR_systolic_BP) |
PSS008596| Greater Middle Eastern Ancestry| 1,151 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Systolic blood pressure, automated reading | — | — | Partial Correlation (partial-r): 0.2284 [0.1724, 0.2829] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010950 | PGS002009 (portability-PLR_systolic_BP) |
PSS008374| South Asian Ancestry| 6,098 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Systolic blood pressure, automated reading | — | — | Partial Correlation (partial-r): 0.1877 [0.1633, 0.2118] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010951 | PGS002009 (portability-PLR_systolic_BP) |
PSS008150| East Asian Ancestry| 1,719 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Systolic blood pressure, automated reading | — | — | Partial Correlation (partial-r): 0.2163 [0.1705, 0.2612] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010953 | PGS002009 (portability-PLR_systolic_BP) |
PSS009042| African Ancestry| 3,850 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Systolic blood pressure, automated reading | — | — | Partial Correlation (partial-r): 0.1046 [0.0732, 0.1358] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010952 | PGS002009 (portability-PLR_systolic_BP) |
PSS007938| African Ancestry| 2,438 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Systolic blood pressure, automated reading | — | — | Partial Correlation (partial-r): 0.104 [0.0644, 0.1433] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM012670 | PGS002228 (portability-ldpred2_systolic_BP) |
PSS009494| European Ancestry| 18,717 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Systolic blood pressure, automated reading | — | — | Partial Correlation (partial-r): 0.2585 [0.2451, 0.2718] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM012671 | PGS002228 (portability-ldpred2_systolic_BP) |
PSS009268| European Ancestry| 3,930 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Systolic blood pressure, automated reading | — | — | Partial Correlation (partial-r): 0.2775 [0.2483, 0.3061] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM012672 | PGS002228 (portability-ldpred2_systolic_BP) |
PSS008822| European Ancestry| 6,337 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Systolic blood pressure, automated reading | — | — | Partial Correlation (partial-r): 0.2265 [0.203, 0.2498] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM012673 | PGS002228 (portability-ldpred2_systolic_BP) |
PSS008596| Greater Middle Eastern Ancestry| 1,151 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Systolic blood pressure, automated reading | — | — | Partial Correlation (partial-r): 0.2233 [0.1672, 0.278] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM012674 | PGS002228 (portability-ldpred2_systolic_BP) |
PSS008374| South Asian Ancestry| 6,098 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Systolic blood pressure, automated reading | — | — | Partial Correlation (partial-r): 0.1982 [0.1739, 0.2222] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM012675 | PGS002228 (portability-ldpred2_systolic_BP) |
PSS008150| East Asian Ancestry| 1,719 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Systolic blood pressure, automated reading | — | — | Partial Correlation (partial-r): 0.198 [0.1519, 0.2433] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM012676 | PGS002228 (portability-ldpred2_systolic_BP) |
PSS007938| African Ancestry| 2,438 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Systolic blood pressure, automated reading | — | — | Partial Correlation (partial-r): 0.0959 [0.0563, 0.1353] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM012677 | PGS002228 (portability-ldpred2_systolic_BP) |
PSS009042| African Ancestry| 3,850 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Systolic blood pressure, automated reading | — | — | Partial Correlation (partial-r): 0.0994 [0.0679, 0.1306] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM012835 | PGS002257 (GRS901_SBP) |
PSS009574| European Ancestry| 14,004 individuals |
PGP000283 | Evangelou E et al. Nat Genet (2018) |
Reported Trait: Systolic blood pressure | β: 2.06 [1.79, 2.32] | — | — | — | *Note performance is based on the average between GRS901_SBP and GRS_901_DBP |
| PPM012836 | PGS002257 (GRS901_SBP) |
PSS009574| European Ancestry| 14,004 individuals |
PGP000283 | Evangelou E et al. Nat Genet (2018) |
Reported Trait: Diastolic blood pressure | β: 1.64 [1.46, 1.81] | — | — | — | *Note performance is based on the average between GRS901_SBP and GRS_901_DBP |
| PPM012837 | PGS002257 (GRS901_SBP) |
PSS009574| European Ancestry| 14,004 individuals |
PGP000283 | Evangelou E et al. Nat Genet (2018) |
Reported Trait: Pulse pressure | β: 0.42 [0.25, 0.58] | — | — | — | *Note performance is based on the average between GRS901_SBP and GRS_901_DBP |
| PPM012838 | PGS002257 (GRS901_SBP) |
PSS009574| European Ancestry| 14,004 individuals |
PGP000283 | Evangelou E et al. Nat Genet (2018) |
Reported Trait: Hypertension | OR: 1.27 [1.23, 1.32] | — | — | — | *Note performance is based on the average between GRS901_SBP and GRS_901_DBP |
| PPM012839 | PGS002257 (GRS901_SBP) |
PSS009575| African Ancestry| 6,970 individuals |
PGP000283 | Evangelou E et al. Nat Genet (2018) |
Reported Trait: Systolic blood pressure | β: 2.38 [1.85, 2.9] | — | — | — | *Note performance is based on the average between GRS901_SBP and GRS_901_DBP |
| PPM012840 | PGS002257 (GRS901_SBP) |
PSS009575| African Ancestry| 6,970 individuals |
PGP000283 | Evangelou E et al. Nat Genet (2018) |
Reported Trait: Diastolic blood pressure | β: 1.39 [1.09, 1.7] | — | — | — | *Note performance is based on the average between GRS901_SBP and GRS_901_DBP |
| PPM012841 | PGS002257 (GRS901_SBP) |
PSS009575| African Ancestry| 6,970 individuals |
PGP000283 | Evangelou E et al. Nat Genet (2018) |
Reported Trait: Pulse pressure | β: 0.99 [0.65, 1.32] | — | — | — | *Note performance is based on the average between GRS901_SBP and GRS_901_DBP |
| PPM012842 | PGS002257 (GRS901_SBP) |
PSS009575| African Ancestry| 6,970 individuals |
PGP000283 | Evangelou E et al. Nat Genet (2018) |
Reported Trait: Hypertension | OR: 1.26 [1.2, 1.33] | — | — | — | *Note performance is based on the average between GRS901_SBP and GRS_901_DBP |
| PPM012843 | PGS002257 (GRS901_SBP) |
PSS009576| South Asian Ancestry| 8,827 individuals |
PGP000283 | Evangelou E et al. Nat Genet (2018) |
Reported Trait: Systolic blood pressure | β: 2.58 [2.13, 3.03] | — | — | — | *Note performance is based on the average between GRS901_SBP and GRS_901_DBP |
| PPM012844 | PGS002257 (GRS901_SBP) |
PSS009576| South Asian Ancestry| 8,827 individuals |
PGP000283 | Evangelou E et al. Nat Genet (2018) |
Reported Trait: Diastolic blood pressure | β: 1.49 [1.25, 1.74] | — | — | — | *Note performance is based on the average between GRS901_SBP and GRS_901_DBP |
| PPM012845 | PGS002257 (GRS901_SBP) |
PSS009576| South Asian Ancestry| 8,827 individuals |
PGP000283 | Evangelou E et al. Nat Genet (2018) |
Reported Trait: Pulse pressure | β: 1.09 [0.8, 1.39] | — | — | — | *Note performance is based on the average between GRS901_SBP and GRS_901_DBP |
| PPM012846 | PGS002257 (GRS901_SBP) |
PSS009576| South Asian Ancestry| 8,827 individuals |
PGP000283 | Evangelou E et al. Nat Genet (2018) |
Reported Trait: Hypertension | OR: 1.3 [1.24, 1.36] | — | — | — | *Note performance is based on the average between GRS901_SBP and GRS_901_DBP |
| PPM012863 | PGS002257 (GRS901_SBP) |
PSS009584| European Ancestry| 55,439 individuals |
PGP000284 | Tapela NM et al. Eur J Prev Cardiol (2021) |Ext. |
Reported Trait: Uncontrolled hypertension | — | — | Odds Ratio (OR, top vs. bottom quintile): 1.7 [1.6, 1.8] | age, sex, socioeconomic characteristics (education, occupation, Townsend deprivation score, and country of residence), metabolic and lifestyle CVD risk factors (smoking status, body mass index, physical activity in METS, and weekly alcohol consumption), family history of CVD (diagnosis at any age), number of antihypertensives and the first four principal components of genetic ancestry, genotyping array and LDL-C value at baseline | 881 SNPs remained after QC |
| PPM012864 | PGS002257 (GRS901_SBP) |
PSS009581| European Ancestry| 55,439 individuals |
PGP000284 | Tapela NM et al. Eur J Prev Cardiol (2021) |Ext. |
Reported Trait: Incident major adverse cardiovascular events in hypertension treatment | — | — | Hazard Ratio (HR, top vs. bottom quintile): 1.13 [1.04, 1.23] | age, sex, socioeconomic characteristics (education, occupation, Townsend deprivation score, and country of residence), metabolic and lifestyle CVD risk factors (smoking status, body mass index, physical activity in METS, and weekly alcohol consumption), family history of CVD (diagnosis at any age), number of antihypertensives and the first four principal components of genetic ancestry, genotyping array and LDL-C value at baseline | 881 SNPs remained after QC |
| PPM012865 | PGS002257 (GRS901_SBP) |
PSS009582| European Ancestry| 55,439 individuals |
PGP000284 | Tapela NM et al. Eur J Prev Cardiol (2021) |Ext. |
Reported Trait: Incident myocardial infarction in hypertension treatment | — | — | Hazard Ratio (HR, top vs. bottom quintile): 1.08 [0.97, 1.2] | age, sex, socioeconomic characteristics (education, occupation, Townsend deprivation score, and country of residence), metabolic and lifestyle CVD risk factors (smoking status, body mass index, physical activity in METS, and weekly alcohol consumption), family history of CVD (diagnosis at any age), number of antihypertensives and the first four principal components of genetic ancestry, genotyping array and LDL-C value at baseline | 881 SNPs remained after QC |
| PPM012866 | PGS002257 (GRS901_SBP) |
PSS009583| European Ancestry| 55,439 individuals |
PGP000284 | Tapela NM et al. Eur J Prev Cardiol (2021) |Ext. |
Reported Trait: Incident stroke in hypertension treatment | — | — | Hazard Ratio (HR, top vs. bottom quintile): 1.22 [1.06, 1.41] | age, sex, socioeconomic characteristics (education, occupation, Townsend deprivation score, and country of residence), metabolic and lifestyle CVD risk factors (smoking status, body mass index, physical activity in METS, and weekly alcohol consumption), family history of CVD (diagnosis at any age), number of antihypertensives and the first four principal components of genetic ancestry, genotyping array and LDL-C value at baseline | 881 SNPs remained after QC |
| PPM012945 | PGS002275 (SBP-PRS) |
PSS009627| European Ancestry| 4,416 individuals |
PGP000303 | Groenland EH et al. Atherosclerosis (2022) |
Reported Trait: Systolic blood pressure | β: 3.19 [2.6, 3.78] | — | — | Age, sex, the first 5 principal components, BMI, T2DM, smoking, alcohol use, LDL-cholesterol, eGFR, triglycerides, antihypertensive medication | — |
|
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| PSS009042 | — | — | 3,850 individuals | — | African unspecified | Nigeria (West Africa) | UKB | — |
| PSS009627 | — | — | 4,416 individuals, 75.0 % Male samples |
European | — | UCC-SMART | UCC-SMART | |
| PSS008150 | — | — | 1,719 individuals | — | East Asian | China (East Asia) | UKB | — |
| PSS007266 | — | — | 6,409 individuals | — | African unspecified | — | UKB | — |
| PSS007267 | — | — | 1,634 individuals | — | East Asian | — | UKB | — |
| PSS007268 | — | — | 23,726 individuals | — | European | non-white British ancestry | UKB | — |
| PSS007269 | — | — | 7,640 individuals | — | South Asian | — | UKB | — |
| PSS007270 | — | — | 63,823 individuals | — | European | white British ancestry | UKB | Testing cohort (heldout set) |
| PSS000371 | Individuals who have been referred to a child psychiatric outpatient clinic in the Northern Netherlands before the age of 11. We measured weight and height using regularly calibrated equipment (scales and stadiometer models 770 and 214, respectively; Seca, Hamburg, Germany). Body mass index (BMI; in kg/m2) was also calculated. We measured waist circumference at the midpoint between the lower costal margin and the iliac crest. The hip circumference was measured over both trochanter majores (tangible bone on the outside of the hip joint). Waist to hip ratio was also calculated. We performed all measurements in duplicate, and, if the difference between these measurements exceeded a predefined value, a third measurement was performed. All available measurements were used to calculate means. Heart rate, systolic (SBP) and diastolic (DBP) blood pressure were measured in duplicate with a Dinamap Critikon 1846SX (Critikon Inc, Tampa, FL), from which we calculated means. At the third visit, fasting blood sample of participants were drawn for the measurement of glucose (Roche Diagnostics, Basel, Switzerland), insulin (Diagnostic Systems Laboratories Inc, Webster, TX), HbA1c (high performance liquid chromatography, Variant, Bio-Rad), triglycerides, total cholesterol, HDL cholesterol (Roche Diagnostics) and LDL cholesterol (calculated according to Friedewald’s equation5), as well as alanine transaminase (Photometric determination according to the reference method of the International Federation of Clinical Chemistry (IFCC)6) and lipoprotein(a) (Nephelometric method, BN2, DadeBehring). Serum creatinine was measured by photometric determination with the Jaffé method without deproteinisation (Ecoline® MEGA, DiaSys Diagnostic Systems GmbH. Merck). eGFR for adolescents who were younger than 18 years old was calculated using the Schwartz formula.7 High‐sensitivity C‐reactive protein (hsCRP) was determined using an immunonephelometric method, BN2 (CardioPhase hsCRP, Siemens) with a lower detection limit of 0.175 mg/L. Total IgE measurements were performed using the Phadia Immunocap 100 system with fluoroenzyme immunoassay (FEIA). | — | 288 individuals, 69.2 % Male samples |
Mean = 15.83 years Sd = 0.6 years |
European | — | TRAILS, TRAILSCC | TRAILS Clinical Cohort |
| PSS008822 | — | — | 6,337 individuals | — | European | Italy (South Europe) | UKB | — |
| PSS000376 | We measured weight and height using regularly calibrated equipment (scales and stadiometer models 770 and 214, respectively; Seca, Hamburg, Germany). Body mass index (BMI; in kg/m2) was also calculated. We measured waist circumference at the midpoint between the lower costal margin and the iliac crest. The hip circumference was measured over both trochanter majores (tangible bone on the outside of the hip joint). Waist to hip ratio was also calculated. We performed all measurements in duplicate, and, if the difference between these measurements exceeded a predefined value, a third measurement was performed. All available measurements were used to calculate means. Heart rate, systolic (SBP) and diastolic (DBP) blood pressure were measured in duplicate with a Dinamap Critikon 1846SX (Critikon Inc, Tampa, FL), from which we calculated means. At the third visit, fasting blood sample of participants were drawn for the measurement of glucose (Roche Diagnostics, Basel, Switzerland), insulin (Diagnostic Systems Laboratories Inc, Webster, TX), HbA1c (high performance liquid chromatography, Variant, Bio-Rad), triglycerides, total cholesterol, HDL cholesterol (Roche Diagnostics) and LDL cholesterol (calculated according to Friedewald’s equation5), as well as alanine transaminase (Photometric determination according to the reference method of the International Federation of Clinical Chemistry (IFCC)6) and lipoprotein(a) (Nephelometric method, BN2, DadeBehring). Serum creatinine was measured by photometric determination with the Jaffé method without deproteinisation (Ecoline® MEGA, DiaSys Diagnostic Systems GmbH. Merck). eGFR for adolescents who were younger than 18 years old was calculated using the Schwartz formula.7 High‐sensitivity C‐reactive protein (hsCRP) was determined using an immunonephelometric method, BN2 (CardioPhase hsCRP, Siemens) with a lower detection limit of 0.175 mg/L. Total IgE measurements were performed using the Phadia Immunocap 100 system with fluoroenzyme immunoassay (FEIA). | — | 1,354 individuals, 47.56 % Male samples |
Mean = 16.22 years Sd = 0.66 years |
European | — | TRAILS | — |
| PSS007938 | — | — | 2,438 individuals | — | African American or Afro-Caribbean | Carribean | UKB | — |
| PSS008596 | — | — | 1,151 individuals | — | Greater Middle Eastern (Middle Eastern, North African or Persian) | Iran (Middle East) | UKB | — |
| PSS009494 | — | — | 18,717 individuals | — | European | UK (+ Ireland) | UKB | — |
| PSS001169 | Cases were individuals with hypertension. Of the 27,804 cases, 13,279 had early-onset hypertension (age of onset < 55 years) whilst 14,525 had late-onset hypertension (age of onset ≥ 55 years). | — | [ ,
0.0 % Male samples |
— | European (Finnish) |
— | FinnGen | — |
| PSS001170 | Cases were individuals with hypertension. Of the 28,113 cases, 14,082 had early-onset hypertension (age of onset < 55 years) whilst 14,031 had late-onset hypertension (age of onset ≥ 55 years). | — | [ ,
100.0 % Male samples |
— | European (Finnish) |
— | FinnGen | — |
| PSS009574 | — | — | 14,004 individuals | — | European | — | Airwave | — |
| PSS009575 | — | — | 6,970 individuals | — | African unspecified | — | UKB | — |
| PSS009576 | — | — | 8,827 individuals | — | South Asian | — | UKB | — |
| PSS009268 | — | — | 3,930 individuals | — | European | Poland (NE Europe) | UKB | — |
| PSS008374 | — | — | 6,098 individuals | — | South Asian | India (South Asia) | UKB | — |
| PSS009581 | The treated hypertension sub-cohort was participants who were presently taking antihypertensive medications (indicated by selecting ‘blood pressure medication’ in response to the question ‘Do you regularly take any of the following medications?’ or reporting an antihypertensive medication in a verbal interview with a trained nurse). The antihypertensive medication classes considered were beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium-channel blocker, alpha blockers, and diuretics. Uncontrolled hypertension was defined as having a mean systolic BP >_140 mmHg or mean diastolic BP >_90 mmHg, among individuals in the treated hypertension sub-cohort. We used prospective follow-up data to assess the composite outcome of incident major adverse cardiovascular events (MACE), which we defined as the first non-fatal stroke (ischaemic or haemorrhagic), non-fatal myocardial infarction, or fatal cardiovascular events, or disease-modifying cardiovascular procedures. We identified MACE components using International Classification of Diseases (ICD-9 and ICD-10) and the Office of Population Censuses and Surveys Classification of Interventions and Procedures version 4 (OPCS-4) codes from Hospital Episodes Statistics (HES) data, and death registries data. | Median = 11.5 years | [ ,
51.0 % Male samples |
Mean = 61.0 years | European (white British) |
— | UKB | — |
| PSS009582 | The treated hypertension sub-cohort was participants who were presently taking antihypertensive medications (indicated by selecting ‘blood pressure medication’ in response to the question ‘Do you regularly take any of the following medications?’ or reporting an antihypertensive medication in a verbal interview with a trained nurse). The antihypertensive medication classes considered were beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium-channel blocker, alpha blockers, and diuretics. Uncontrolled hypertension was defined as having a mean systolic BP >_140 mmHg or mean diastolic BP >_90 mmHg, among individuals in the treated hypertension sub-cohort. We used prospective follow-up data to assess the composite outcome of incident major adverse cardiovascular events (MACE), which we defined as the first non-fatal stroke (ischaemic or haemorrhagic), non-fatal myocardial infarction, or fatal cardiovascular events, or disease-modifying cardiovascular procedures. We identified MACE components using International Classification of Diseases (ICD-9 and ICD-10) and the Office of Population Censuses and Surveys Classification of Interventions and Procedures version 4 (OPCS-4) codes from Hospital Episodes Statistics (HES) data, and death registries data. | Median = 11.5 years | [ ,
51.0 % Male samples |
Mean = 61.0 years | European (white British) |
— | UKB | — |
| PSS009583 | The treated hypertension sub-cohort was participants who were presently taking antihypertensive medications (indicated by selecting ‘blood pressure medication’ in response to the question ‘Do you regularly take any of the following medications?’ or reporting an antihypertensive medication in a verbal interview with a trained nurse). The antihypertensive medication classes considered were beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium-channel blocker, alpha blockers, and diuretics. Uncontrolled hypertension was defined as having a mean systolic BP >_140 mmHg or mean diastolic BP >_90 mmHg, among individuals in the treated hypertension sub-cohort. We used prospective follow-up data to assess the composite outcome of incident major adverse cardiovascular events (MACE), which we defined as the first non-fatal stroke (ischaemic or haemorrhagic), non-fatal myocardial infarction, or fatal cardiovascular events, or disease-modifying cardiovascular procedures. We identified MACE components using International Classification of Diseases (ICD-9 and ICD-10) and the Office of Population Censuses and Surveys Classification of Interventions and Procedures version 4 (OPCS-4) codes from Hospital Episodes Statistics (HES) data, and death registries data. | Median = 11.5 years | [ ,
51.0 % Male samples |
Mean = 61.0 years | European (white British) |
— | UKB | — |
| PSS009584 | The treated hypertension sub-cohort was participants who were presently taking antihypertensive medications (indicated by selecting ‘blood pressure medication’ in response to the question ‘Do you regularly take any of the following medications?’ or reporting an antihypertensive medication in a verbal interview with a trained nurse). The antihypertensive medication classes considered were beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium-channel blocker, alpha blockers, and diuretics. Uncontrolled hypertension was defined as having a mean systolic BP >_140 mmHg or mean diastolic BP >_90 mmHg, among individuals in the treated hypertension sub-cohort. We used prospective follow-up data to assess the composite outcome of incident major adverse cardiovascular events (MACE), which we defined as the first non-fatal stroke (ischaemic or haemorrhagic), non-fatal myocardial infarction, or fatal cardiovascular events, or disease-modifying cardiovascular procedures. We identified MACE components using International Classification of Diseases (ICD-9 and ICD-10) and the Office of Population Censuses and Surveys Classification of Interventions and Procedures version 4 (OPCS-4) codes from Hospital Episodes Statistics (HES) data, and death registries data. | Median = 11.5 years | [ ,
51.0 % Male samples |
Mean = 61.0 years | European (white British) |
— | UKB | — |
| PSS001446 | Cases were individuals with incident hypertension. Hypertension was defined as persistently high systemic arterial blood pressure based on multiple blood pressure readings (consistent systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg) or medical expenses reimbursement history. Diagnoses were based on the International Classification of Diseases (ICD) 8 codes (I1[0-3]/I15/I674) , ICD-9 codes (I1[0-3]/I15/I674), and ICD-10 codes (I1[0-3]/I15/I674). Of the 55,917 cases, 27,361 had early-onset incident hypertension, whilst 28,556 had late-onset incident hypertension. Early-onset and late-onset hypertension were defined as age of onset <55 and ≥55 years, respectively. | — | [
|
— | European (Finnish) |
— | FinnGen | — |
| PSS001447 | Cases were individuals with incident coronary heart disease (CHD). CHD was defined as Major coronary heart disease event: coronary revascularization (angioplasty or bypass grafting) or myocardial infarction. Diagnoses were based on the International Classification of Diseases (ICD) 8 codes (410/4110) , ICD-9 codes (410), and ICD-10 codes (I200/I21/I22). | — | [ ,
44.0 % Male samples |
Mean = 58.0 years | European (Finnish) |
— | FinnGen | — |
| PSS001448 | Cases were individuals with incident cardiovascular disease (CVD). CVD was defined as ard cardiovascular diseases: coronary heart disease or stroke. | — | [ ,
44.0 % Male samples |
Mean = 58.0 years | European (Finnish) |
— | FinnGen | — |
| PSS001449 | Cases were individuals with incident stroke. Stroke was defined as stroke, excluding subarachnoid hemorrhage. Diagnoses were based on the International Classification of Diseases (ICD) 8 codes (431/433/434/436) , ICD-9 codes (431/4330A/4331A/4339A/4340A/4341A/4349A/436), and ICD-10 codes (I61/I63/I64 (excluding I636)). | — | [
|
— | European (Finnish) |
— | FinnGen | — |
| PSS001450 | Cases were individuals with incident hypertension. Hypertension was defined as persistently high systemic arterial blood pressure based on multiple blood pressure readings (consistent systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg) or medical expenses reimbursement history. Diagnoses were based on the International Classification of Diseases (ICD) 8 codes (I1[0-3]/I15/I674) , ICD-9 codes (I1[0-3]/I15/I674), and ICD-10 codes (I1[0-3]/I15/I674). | — | [
|
— | European (Finnish) |
— | FINRISK | — |